ClinicalTrials.gg
CompletedNCT04666298ORION-15Updated Jun 20, 2024Results posted

Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C

A Phase 2 interventional study of Inclisiran sodium and Placebo in Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, sponsored by Novartis Pharmaceuticals. Completed at 42 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-06-20.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing inclisiran in Hypercholesterolemia — 6 open to participants now, 10 under way, 5 of them phase 3. inclisiran · Hypercholesterolemia.

Enrollment
15th of 24
312 · median 375
Started
2021
with 4 others
Phase 2
2 of 24
1 open now
Registered
7th of 24
by date
Lead sponsor
16 of 24
Novartis Pharmaceuticals

Among the 24 studies testing inclisiran in Hypercholesterolemia, this one is the 15th largest by enrollment, is one of 5 that started in 2021, is one of 2 in phase 2, and was the 7th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

6 of the 24 studies testing inclisiran in Hypercholesterolemia are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About inclisiran

inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing inclisiran in Hypercholesterolemia, or all of them as a file.
02

Study summary

This was a placebo-controlled, double-blind, randomized trial in Japanese participants with history of coronary artery disease (CAD) or participants categorized in 'high risk' by JAS 2017 guideline, or Japanese participants with heterozygous familial hypercholesterolemia (HeFH) and elevated Low-density lipoprotein cholesterol (LDL-C) despite maximum tolerated dose of statin(s) to evaluate the efficacy, safety, tolerability, and PK of subcutaneous inclisiran injection(s).

Read the detailed description

The expected duration of the participants' involvement in the study was approximately 374 days which included screening (up to 14 days), Day 1 study drug administration, two additional injections on Day 90 and Day 270, and the follow-up period to Day 360.

The primary analysis was conducted after all participants had finished Day 180 visit assessments or discontinued before Day 180 visit.

After the primary analysis, double-blind treatment period were maintained to Day 360, although specific sponsor members (except for blinded monitors) were unblinded for the regulatory submission in Japan.

03

Conditions studied

  • Hypercholesterolemia
  • Heterozygous Familial Hypercholesterolemia

Keywords

  • inclisiran
  • siRNA
  • dyslipidemia
  • PCSK9
  • Hypercholesterolemia
  • LDL-C
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with history of CAD or participants categorized in 'high risk' by Japan Atherosclerosis Society (JAS) 2017 guidelines or participants with heterozygous familial hypercholesterolemia (HeFH)
  • As per the JAS 2017 guideline, participants not meeting the LDL-C management targets.
  • Participants on statins should be receiving a maximally tolerated dose.
  • Participants not receiving statins must have documented evidence of intolerance to at least one statin.
  • The lipid-lowering therapy should have remained stable for ≥ 30 days before screening with no planned medication/ dose change until Day 180

Exclusion criteria

Exclusion Criteria:

  • Participants diagnosed with homozygous familial hypercholesterolemia (HoFH).
  • Treatment (within 90 days of screening) with monoclonal antibodies directed towards PCSK9.
  • (NYHA) class IV heart failure or last known \<25%.
  • Cardiac arrhythmia within 3 months prior to randomization that is not controlled by medication or via ablation.
  • Uncontrolled hypertension: systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg prior to randomization despite antihypertensive therapy.
  • Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in (ALT), aspartate aminotransferase (AST), >3x the (ULN), or total >2x ULN at screening.
  • Severe concomitant non-cardiovascular disease that carries the risk of reducing to less than 2 years.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
312 participants (actual)

Study arms

  • Experimental
    300 mg inclisiran sodium

    Subcutaneous injection

    Drug: Inclisiran sodium

  • Experimental
    200 mg inclisiran sodium

    Subcutaneous injection

    Drug: Inclisiran sodium

  • Experimental
    100 mg inclisiran sodium

    Subcutaneous injection

    Drug: Inclisiran sodium

  • Placebo comparator
    Placebo

    Subcutaneous injection

    Drug: Placebo

Interventions

  • Subcutaneously injected on Day 1, 90 and 270.

    Also known as: KJX839

  • DrugPlacebo

    Subcutaneously injected on Day 1, 90, and 270.

    Also known as: KJX839 placebo

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) to Day 180

    Percent change from baseline in LDL-C was calculated to evaluate the effect of inclisiran at Day 180. Difference between different inclisiran dose groups and the placebo group in percentage change in LDL-C levels from baseline to Day 180 were calculated to capture both, the effect of the study drug and the effect of additional medications, mirroring the conditions in clinical practice. An MMRM (Mixed-effect Model with Repeated Measurement) was used as the primary analysis model, with treatment group, visits, interaction between visits and treatment groups, current use of statins or other lipid-modifying therapies as fixed effects, and baseline LDL-C as a continuous covariate.

    Time frame: Baseline, Day 180

Secondary outcomes

  1. Percent Change From Baseline in PCSK9 by Visit

    Percent change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9) was calculated to evaluate the effect of inclisiran over time.

    Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180

  2. Percent Change From Baseline in LDL-C by Visit

    Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) was calculated to evaluate the effect of inclisiran over time.

    Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120 and day 150

  3. Absolute Change in LDL-C From Baseline at Day 180

    Absolute change from baseline in low-density lipoprotein cholesterol (LDL-C) was calculated to evaluate the effect of inclisiran until Day 180.

    Time frame: Baseline, Day 180

  4. Proportion of Participants With LDL-C Greater Than 80% of Baseline Value at Day 180

    Proportion of participants with LDL-C greater than 80% of baseline value at Day 180 was calculated to evaluate the effect of inclisiran until Day 180. Subjects are counted if the LDL-C value is greater than '0.8\*(LDL-C at Baseline - LDL-C at Day180) + LDL-C at Day180', or the LDL-C value is greater than or equal to the LDL-C at Baseline.

    Time frame: Baseline, Day 180

  5. Proportion of Participants With Greater or Equal to 50% LDL-C Reduction From Baseline by Visit

    Proportion of participants with greater or equal to 50% LDL-C reduction from baseline was calculated to evaluate the effect of inclisiran over time.

    Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180

  6. Percent Change From Baseline in Cholesterol by Visit

    Percent change from baseline in cholesterol by visit was calculated to evaluate the effect of inclisiran over time

    Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180

  7. Percent Change From Baseline in Triglycerides by Visit

    Percent change from baseline in triglycerides by visit was calculated to evaluate the effect of inclisiran over time

    Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180

  8. Percent Change From Baseline in HDL Cholesterol by Visit

    Percent change from baseline in high-density lipoprotein cholesterol (HDL-C) by visit was calculated to evaluate the effect of inclisiran over time

    Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180

  9. Percent Change From Baseline in Non-HDL Cholesterol by Visit

    Percent change from baseline in non-HDL Cholesterol by visit was calculated to evaluate the effect of inclisiran over time

    Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180

  10. Percent Change From Baseline in VLDL-C by Visit

    Percent change from baseline in very low-density lipoprotein cholesterol (VLDL - C) by visit was calculated to evaluate the effect of inclisiran over time

    Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180

  11. Percent Change From Baseline in Apo- A1 by Visit

    Percent change from baseline in Apolipoprotein A1 (Apo-A1) by visit was calculated to evaluate the effect of inclisiran over time

    Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180

  12. Percent Change From Baseline in Apo- B by Visit

    Percent change from baseline in Apolipoprotein B (Apo-B) by visit was calculated to evaluate the effect of inclisiran over time

    Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180

  13. Percent Change From Baseline in Lipoprotein-a by Visit

    Percent change from baseline in Lipoprotein a (LP(a)) by visit was calculated to evaluate the effect of inclisiran over time

    Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180

  14. Proportion of Participants Who Attain Lipid Control Target Pre-specified by JAS 2017 Guidelines for Their Level of Cardiovascular Risk at Day 180

    Proportion of participants who attain lipid control target pre-specified by Japan Atherosclerosis Society(JAS) 2017 guidelines for their level of cardiovascular risk at Day 180 was calculated to evaluate the effect of inclisiran.

    Time frame: Day 180

  15. Number of Participants With LDL-C Levels of <25 mg/dL, <50 mg/dL, <70 mg/dL, and <100 mg/dL by Visit

    Number of participants by LDL-C levels was calculated to evaluate the effect of inclisiran.

    Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180

07

Results

Posted May 10, 2023

Participant flow

Participant flow — Overall Study
MilestonePlacebo100 mg Inclisiran Sodium200 mg Inclisiran Sodium300 mg Inclisiran Sodium
Started575510199
Completed555510095
Not completed2014
Withdrew: Subject decision1002
Withdrew: Death1000
Withdrew: Lost to follow-up0001
Withdrew: Physician decision0001
Withdrew: Protocol deviation0010

Outcome measures

PrimaryPercent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) to Day 180

Percent change from baseline in LDL-C was calculated to evaluate the effect of inclisiran at Day 180. Difference between different inclisiran dose groups and the placebo group in percentage change in LDL-C levels from baseline to Day 180 were calculated to capture both, the effect of the study drug and the effect of additional medications, mirroring the conditions in clinical practice. An MMRM (Mixed-effect Model with Repeated Measurement) was used as the primary analysis model, with treatment group, visits, interaction between visits and treatment groups, current use of statins or other lipid-modifying therapies as fixed effects, and baseline LDL-C as a continuous covariate.

Time frame:
Baseline, Day 180
Reported as:
Least squares mean · percent change in LDL-C
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) to Day 180
percent change in LDL-CPlacebo100 mg Inclisiran Sodium200 mg Inclisiran Sodium300 mg Inclisiran Sodium
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) to Day 1809.0 (3.5 to 14.5)-47.6 (-53.4 to -41.8)-51.9 (-56.8 to -47.0)-56.3 (-61.1 to -51.4)
Statistical analysis
  • Placebo vs 100 mg Inclisiran Sodium · Mixed Models Analysis · p = <.0001 (One-sided adjusted p-value for multiple comparisons using Dunnett´s multiple t-test) · Mean difference (net): -56.6 · 95% CI -64.2 to -49.0
  • Placebo vs 200 mg Inclisiran Sodium · Mixed Models Analysis · p = <.0001 (One-sided adjusted p-value for multiple comparisons using Dunnett´s multiple t-test) · Mean difference (net): -60.9 · 95% CI -67.6 to -54.3
  • Placebo vs 300 mg Inclisiran Sodium · Mixed Models Analysis · p = <.0001 (One-sided adjusted p-value for multiple comparisons using Dunnett´s multiple t-test) · Mean difference (net): -65.3 · 95% CI -72.0 to -58.6
SecondaryPercent Change From Baseline in PCSK9 by Visit

Percent change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9) was calculated to evaluate the effect of inclisiran over time.

Time frame:
Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180
Reported as:
Mean · percent change in PCSK9
Percent Change From Baseline in PCSK9 by Visit
percent change in PCSK9Placebo100 mg Inclisiran Sodium200 mg Inclisiran Sodium300 mg Inclisiran Sodium
Day 144.79 ± 21.623-55.42 ± 19.980-65.64 ± 13.677-69.56 ± 11.387
Day 301.92 ± 22.427-66.45 ± 12.341-72.94 ± 8.809-76.46 ± 8.561
Day 60-0.16 ± 22.656-62.56 ± 15.356-73.23 ± 10.692-76.52 ± 9.953
Day 902.12 ± 21.447-59.76 ± 14.503-70.49 ± 10.806-73.09 ± 11.525
Day 1042.65 ± 28.624-69.05 ± 11.109-76.23 ± 9.017-78.55 ± 8.052
Day 1200.99 ± 21.572-70.29 ± 11.543-77.03 ± 8.206-79.80 ± 6.994
Day 1502.34 ± 23.353-66.02 ± 12.724-73.94 ± 17.139-77.12 ± 8.770
Day 1802.78 ± 21.226-63.62 ± 14.012-70.99 ± 10.495-75.97 ± 9.885
SecondaryPercent Change From Baseline in LDL-C by Visit

Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) was calculated to evaluate the effect of inclisiran over time.

Time frame:
Baseline, day 14, day 30, day 60, day 90, day 104, day 120 and day 150
Reported as:
Mean · percent change in LDL-C
Percent Change From Baseline in LDL-C by Visit
percent change in LDL-CPlacebo100 mg Inclisiran Sodium200 mg Inclisiran Sodium300 mg Inclisiran Sodium
Day 141.68 ± 18.099-37.15 ± 21.855-42.08 ± 20.503-47.60 ± 19.889
Day 301.29 ± 13.068-52.20 ± 18.389-55.54 ± 17.501-62.77 ± 15.097
Day 600.24 ± 15.314-50.06 ± 19.173-55.61 ± 17.570-62.35 ± 13.976
Day 902.69 ± 14.332-46.39 ± 17.872-53.92 ± 17.186-61.51 ± 15.480
Day 1041.20 ± 13.519-53.00 ± 19.001-60.33 ± 15.912-65.68 ± 15.321
Day 1202.26 ± 14.854-54.91 ± 19.410-62.04 ± 16.742-67.23 ± 16.017
Day 1504.27 ± 16.983-55.46 ± 18.817-60.55 ± 16.502-66.15 ± 15.197
SecondaryAbsolute Change in LDL-C From Baseline at Day 180

Absolute change from baseline in low-density lipoprotein cholesterol (LDL-C) was calculated to evaluate the effect of inclisiran until Day 180.

Time frame:
Baseline, Day 180
Reported as:
Least squares mean · mg/dL
Absolute Change in LDL-C From Baseline at Day 180
mg/dLPlacebo100 mg Inclisiran Sodium200 mg Inclisiran Sodium300 mg Inclisiran Sodium
Absolute Change in LDL-C From Baseline at Day 18013.2 (6.6 to 19.8)-49.3 (-56.2 to -42.3)-53.9 (-59.8 to -48.0)-57.7 (-63.5 to -51.8)
SecondaryProportion of Participants With LDL-C Greater Than 80% of Baseline Value at Day 180

Proportion of participants with LDL-C greater than 80% of baseline value at Day 180 was calculated to evaluate the effect of inclisiran until Day 180. Subjects are counted if the LDL-C value is greater than '0.8\*(LDL-C at Baseline - LDL-C at Day180) + LDL-C at Day180', or the LDL-C value is greater than or equal to the LDL-C at Baseline.

Time frame:
Baseline, Day 180
Reported as:
Count of participants · Participants
Proportion of Participants With LDL-C Greater Than 80% of Baseline Value at Day 180
ParticipantsPlacebo100 mg Inclisiran Sodium200 mg Inclisiran Sodium300 mg Inclisiran Sodium
Proportion of Participants With LDL-C Greater Than 80% of Baseline Value at Day 18035000
SecondaryProportion of Participants With Greater or Equal to 50% LDL-C Reduction From Baseline by Visit

Proportion of participants with greater or equal to 50% LDL-C reduction from baseline was calculated to evaluate the effect of inclisiran over time.

Time frame:
Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180
Reported as:
Count of participants · Participants
Proportion of Participants With Greater or Equal to 50% LDL-C Reduction From Baseline by Visit
ParticipantsPlacebo100 mg Inclisiran Sodium200 mg Inclisiran Sodium300 mg Inclisiran Sodium
Day 141174045
Day 300316383
Day 600266475
Day 900225876
Day 1040327782
Day 1200377282
Day 1500357378
Day 1800336873
SecondaryPercent Change From Baseline in Cholesterol by Visit

Percent change from baseline in cholesterol by visit was calculated to evaluate the effect of inclisiran over time

Time frame:
Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180
Reported as:
Mean · Percent change in cholesterol
Percent Change From Baseline in Cholesterol by Visit
Percent change in cholesterolPlacebo100 mg Inclisiran Sodium200 mg Inclisiran Sodium300 mg Inclisiran Sodium
Day 140.87 ± 10.399-21.94 ± 14.034-24.71 ± 12.917-28.60 ± 12.476
Day 300.89 ± 9.003-30.92 ± 12.558-32.90 ± 11.739-37.09 ± 10.227
Day 600.31 ± 8.885-29.47 ± 13.426-33.71 ± 12.291-37.01 ± 9.948
Day 901.03 ± 8.952-27.30 ± 13.127-32.26 ± 12.103-36.34 ± 10.655
Day 1041.62 ± 10.178-30.72 ± 13.239-35.63 ± 11.875-39.53 ± 10.468
Day 1201.11 ± 10.860-32.24 ± 13.575-36.24 ± 12.995-39.38 ± 10.165
Day 1502.41 ± 10.801-32.20 ± 14.246-35.70 ± 11.980-38.12 ± 10.850
Day 1802.78 ± 10.272-30.22 ± 12.468-32.95 ± 12.540-35.46 ± 11.941
SecondaryPercent Change From Baseline in Triglycerides by Visit

Percent change from baseline in triglycerides by visit was calculated to evaluate the effect of inclisiran over time

Time frame:
Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180
Reported as:
Mean · percent change in triglycerides
Percent Change From Baseline in Triglycerides by Visit
percent change in triglyceridesPlacebo100 mg Inclisiran Sodium200 mg Inclisiran Sodium300 mg Inclisiran Sodium
Day 145.49 ± 28.8031.24 ± 29.630-1.16 ± 51.241-7.19 ± 23.817
Day 307.76 ± 35.248-4.72 ± 25.843-8.69 ± 25.450-8.37 ± 28.240
Day 609.68 ± 37.000-7.17 ± 28.427-9.26 ± 27.598-9.93 ± 26.405
Day 906.83 ± 33.204-1.87 ± 40.499-12.17 ± 26.204-9.99 ± 29.230
Day 10411.86 ± 37.365-7.12 ± 26.145-5.81 ± 55.419-13.51 ± 26.915
Day 1203.57 ± 33.870-9.40 ± 27.192-9.32 ± 33.471-12.33 ± 26.280
Day 1503.33 ± 32.023-5.60 ± 42.988-12.65 ± 24.766-11.81 ± 28.623
Day 180-0.19 ± 32.161-2.34 ± 33.783-12.11 ± 39.414-13.67 ± 27.307
SecondaryPercent Change From Baseline in HDL Cholesterol by Visit

Percent change from baseline in high-density lipoprotein cholesterol (HDL-C) by visit was calculated to evaluate the effect of inclisiran over time

Time frame:
Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180
Reported as:
Mean · percent change in HDL Cholesterol
Percent Change From Baseline in HDL Cholesterol by Visit
percent change in HDL CholesterolPlacebo100 mg Inclisiran Sodium200 mg Inclisiran Sodium300 mg Inclisiran Sodium
Day 141.73 ± 8.7653.00 ± 10.7455.93 ± 12.1644.38 ± 10.727
Day 301.94 ± 11.2594.86 ± 10.4509.89 ± 13.6568.43 ± 12.740
Day 600.57 ± 10.6776.80 ± 15.2228.02 ± 15.4119.15 ± 14.984
Day 900.56 ± 11.5436.51 ± 16.29710.86 ± 16.3598.59 ± 16.546
Day 1041.35 ± 14.8178.69 ± 15.30311.04 ± 16.4438.99 ± 17.280
Day 1204.20 ± 13.7478.84 ± 13.43212.65 ± 16.77711.97 ± 18.300
Day 1505.12 ± 13.5877.51 ± 17.45512.80 ± 16.33711.68 ± 18.486
Day 1808.25 ± 12.9406.89 ± 17.05115.95 ± 17.02514.26 ± 20.158
SecondaryPercent Change From Baseline in Non-HDL Cholesterol by Visit

Percent change from baseline in non-HDL Cholesterol by visit was calculated to evaluate the effect of inclisiran over time

Time frame:
Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180
Reported as:
Mean · percent change in non-HDL Cholesterol
Percent Change From Baseline in Non-HDL Cholesterol by Visit
percent change in non-HDL CholesterolPlacebo100 mg Inclisiran Sodium200 mg Inclisiran Sodium300 mg Inclisiran Sodium
Day 141.13 ± 13.511-31.37 ± 19.592-35.68 ± 18.056-41.16 ± 17.005
Day 301.03 ± 11.483-44.72 ± 16.270-47.99 ± 15.318-54.17 ± 12.815
Day 600.62 ± 11.841-43.39 ± 16.505-48.18 ± 15.146-54.10 ± 12.034
Day 901.75 ± 11.931-39.83 ± 16.485-47.20 ± 15.002-53.18 ± 13.236
Day 1041.96 ± 12.067-46.10 ± 17.006-51.98 ± 14.344-57.74 ± 12.513
Day 1200.82 ± 14.045-48.22 ± 17.301-53.52 ± 15.425-58.67 ± 12.175
Day 1501.96 ± 13.519-47.90 ± 17.495-52.85 ± 14.254-56.82 ± 12.997
Day 1801.29 ± 13.455-44.83 ± 15.558-50.15 ± 16.446-54.04 ± 14.230
SecondaryPercent Change From Baseline in VLDL-C by Visit

Percent change from baseline in very low-density lipoprotein cholesterol (VLDL - C) by visit was calculated to evaluate the effect of inclisiran over time

Time frame:
Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180
Reported as:
Mean · percent change in VLDL-C
Percent Change From Baseline in VLDL-C by Visit
percent change in VLDL-CPlacebo100 mg Inclisiran Sodium200 mg Inclisiran Sodium300 mg Inclisiran Sodium
Day 145.55 ± 28.428-2.96 ± 31.885-5.56 ± 43.055-12.41 ± 25.589
Day 306.69 ± 33.655-9.01 ± 28.560-13.39 ± 28.081-14.74 ± 30.582
Day 609.40 ± 36.824-10.27 ± 32.555-14.02 ± 28.944-17.94 ± 25.358
Day 906.53 ± 33.387-5.39 ± 41.490-16.70 ± 26.127-15.76 ± 27.957
Day 10411.56 ± 37.588-12.10 ± 28.575-12.54 ± 45.978-24.05 ± 26.076
Day 1203.10 ± 33.707-15.90 ± 30.271-14.05 ± 36.083-22.29 ± 24.030
Day 1503.41 ± 31.791-10.91 ± 45.835-17.49 ± 27.270-18.39 ± 30.321
Day 180-0.30 ± 31.345-7.30 ± 33.946-17.89 ± 33.050-21.74 ± 27.746
SecondaryPercent Change From Baseline in Apo- A1 by Visit

Percent change from baseline in Apolipoprotein A1 (Apo-A1) by visit was calculated to evaluate the effect of inclisiran over time

Time frame:
Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180
Reported as:
Mean · percent change in Apo-A1
Percent Change From Baseline in Apo- A1 by Visit
percent change in Apo-A1Placebo100 mg Inclisiran Sodium200 mg Inclisiran Sodium300 mg Inclisiran Sodium
Day 140.04 ± 8.8723.64 ± 9.2932.29 ± 7.6593.98 ± 7.952
Day 300.90 ± 9.7132.70 ± 10.5534.52 ± 9.3024.35 ± 9.012
Day 600.00 ± 8.5014.71 ± 11.7853.89 ± 10.1965.18 ± 10.023
Day 90-0.35 ± 9.8883.86 ± 11.3535.71 ± 10.6095.21 ± 10.383
Day 1040.14 ± 10.7805.89 ± 13.9225.66 ± 11.0074.99 ± 10.061
Day 1201.79 ± 10.7075.33 ± 12.2936.49 ± 11.3346.60 ± 11.152
Day 1503.70 ± 11.5714.85 ± 14.3307.46 ± 11.5828.35 ± 12.564
Day 1806.09 ± 11.8624.99 ± 14.17010.26 ± 12.2509.09 ± 13.871
SecondaryPercent Change From Baseline in Apo- B by Visit

Percent change from baseline in Apolipoprotein B (Apo-B) by visit was calculated to evaluate the effect of inclisiran over time

Time frame:
Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180
Reported as:
Mean · percent change in Apo-B
Percent Change From Baseline in Apo- B by Visit
percent change in Apo-BPlacebo100 mg Inclisiran Sodium200 mg Inclisiran Sodium300 mg Inclisiran Sodium
Day 141.09 ± 13.795-28.16 ± 16.442-32.45 ± 17.518-37.12 ± 16.743
Day 302.16 ± 12.904-39.72 ± 14.749-43.99 ± 15.185-48.76 ± 12.962
Day 601.41 ± 11.965-39.94 ± 13.996-44.49 ± 14.654-48.53 ± 12.005
Day 902.76 ± 12.882-35.84 ± 14.134-42.04 ± 14.319-46.78 ± 12.611
Day 1043.03 ± 13.304-40.86 ± 14.578-47.03 ± 13.283-51.93 ± 12.390
Day 1202.05 ± 14.719-43.39 ± 14.174-48.18 ± 14.142-51.85 ± 12.414
Day 1503.86 ± 13.559-42.82 ± 14.799-46.71 ± 13.775-50.41 ± 12.411
Day 1803.82 ± 14.649-38.63 ± 13.265-44.50 ± 14.685-46.81 ± 13.968
SecondaryPercent Change From Baseline in Lipoprotein-a by Visit

Percent change from baseline in Lipoprotein a (LP(a)) by visit was calculated to evaluate the effect of inclisiran over time

Time frame:
Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180
Reported as:
Mean · percent change in LP(a)
Percent Change From Baseline in Lipoprotein-a by Visit
percent change in LP(a)Placebo100 mg Inclisiran Sodium200 mg Inclisiran Sodium300 mg Inclisiran Sodium
Day 143.33 ± 32.912-21.77 ± 24.909-16.63 ± 41.372-22.84 ± 22.934
Day 300.92 ± 31.643-28.09 ± 21.846-22.80 ± 46.679-31.30 ± 26.785
Day 60-4.29 ± 30.944-30.89 ± 26.802-26.11 ± 45.964-36.21 ± 22.036
Day 904.35 ± 29.270-27.08 ± 25.260-24.93 ± 42.005-34.26 ± 25.027
Day 104-2.41 ± 26.326-32.02 ± 30.286-25.99 ± 45.444-37.92 ± 30.801
Day 1200.22 ± 23.786-31.46 ± 27.979-30.26 ± 37.382-37.24 ± 25.389
Day 1504.02 ± 32.703-32.21 ± 26.140-21.59 ± 47.820-38.11 ± 24.508
Day 1805.45 ± 36.446-30.15 ± 25.578-25.46 ± 48.279-35.41 ± 25.123
SecondaryProportion of Participants Who Attain Lipid Control Target Pre-specified by JAS 2017 Guidelines for Their Level of Cardiovascular Risk at Day 180

Proportion of participants who attain lipid control target pre-specified by Japan Atherosclerosis Society(JAS) 2017 guidelines for their level of cardiovascular risk at Day 180 was calculated to evaluate the effect of inclisiran.

Time frame:
Day 180
Reported as:
Count of participants · Participants
Proportion of Participants Who Attain Lipid Control Target Pre-specified by JAS 2017 Guidelines for Their Level of Cardiovascular Risk at Day 180
ParticipantsPlacebo100 mg Inclisiran Sodium200 mg Inclisiran Sodium300 mg Inclisiran Sodium
Proportion of Participants Who Attain Lipid Control Target Pre-specified by JAS 2017 Guidelines for Their Level of Cardiovascular Risk at Day 1805508791
SecondaryNumber of Participants With LDL-C Levels of <25 mg/dL, <50 mg/dL, <70 mg/dL, and <100 mg/dL by Visit

Number of participants by LDL-C levels was calculated to evaluate the effect of inclisiran.

Time frame:
Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180
Reported as:
Count of participants · Participants
Number of Participants With LDL-C Levels of <25 mg/dL, <50 mg/dL, <70 mg/dL, and <100 mg/dL by Visit
ParticipantsPlacebo100 mg Inclisiran Sodium200 mg Inclisiran Sodium300 mg Inclisiran Sodium
Day 14: LDL-C <25 mg/dL01510
Day 14: LDL-C <50 mg/dL1193843
Day 14: LDL-C <70 mg/dL3295666
Day 14: LDL-C <100 mg/dL22458186
Day 30: LDL-C <25 mg/dL061420
Day 30: LDL-C <50 mg/dL0305671
Day 30: LDL-C <70 mg/dL3407480
Day 30: LDL-C <100 mg/dL22519394
Day 60: LDL-C <25 mg/dL061423
Day 60: LDL-C <50 mg/dL0285770
Day 60: LDL-C <70 mg/dL5377779
Day 60: LDL-C <100 mg/dL21509292
Day 90: LDL-C <25 mg/dL021221
Day 90: LDL-C <50 mg/dL0275167
Day 90: LDL-C <70 mg/dL1357480
Day 90: LDL-C <100 mg/dL24499394
Day 104: LDL-C <25 mg/dL062227
Day 104: LDL-C <50 mg/dL0306470
Day 104: LDL-C <70 mg/dL4388280
Day 104: LDL-C <100 mg/dL25529592
Day 120: LDL-C <25 mg/dL092532
Day 120: LDL-C <50 mg/dL0326470
Day 120: LDL-C <70 mg/dL3398281
Day 120: LDL-C <100 mg/dL24539591
Day 150: LDL-C <25 mg/dL052431
Day 150: LDL-C <50 mg/dL0326771
Day 150: LDL-C <70 mg/dL2418181
Day 150: LDL-C <100 mg/dL23529593
Day 180: LDL-C <25 mg/dL071326
Day 180: LDL-C <50 mg/dL0305665
Day 180: LDL-C <70 mg/dL2407880
Day 180: LDL-C <100 mg/dL22549490

Adverse events

Collected over Adverse events were reported from first dose of study treatment up to a maximum duration of 360 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/57 (1.8%)6/57 (10.5%)32/57 (56.1%)
Inclisiran 100 mg0/55 (0%)2/55 (3.6%)38/55 (69.1%)
Inclisiran 200 mg0/101 (0%)7/101 (6.9%)59/101 (58.4%)
Inclisiran 300 mg0/99 (0%)7/99 (7.1%)59/99 (59.6%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventPlaceboInclisiran 100 mgInclisiran 200 mgInclisiran 300 mg
Angina unstableCardiac disorders1/571/550/1011/99
Radius fractureInjury, poisoning and procedural complications0/571/550/1010/99
Vitreous haemorrhageEye disorders1/570/550/1010/99
DeathGeneral disorders1/570/550/1010/99
Toxicity to various agentsInjury, poisoning and procedural complications1/570/550/1010/99
Wound dehiscenceInjury, poisoning and procedural complications1/570/550/1010/99
Diabetes mellitus inadequate controlMetabolism and nutrition disorders1/570/551/1010/99
Bladder neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/570/550/1010/99
Embolic cerebral infarctionNervous system disorders1/570/550/1010/99
Cardiac failure congestiveCardiac disorders0/570/550/1011/99
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPlaceboInclisiran 100 mgInclisiran 200 mgInclisiran 300 mg
Diabetes mellitusMetabolism and nutrition disorders5/5711/5512/10112/99
PyrexiaGeneral disorders7/578/5512/10118/99
Diabetes mellitus inadequate controlMetabolism and nutrition disorders9/577/5510/10115/99
COVID-19Infections and infestations2/578/555/1016/99
Vaccination site painGeneral disorders8/571/555/1015/99
Injection site reactionGeneral disorders2/573/5512/1016/99
Back painMusculoskeletal and connective tissue disorders5/576/553/1018/99
MalaiseGeneral disorders6/571/552/1017/99
HeadacheNervous system disorders5/573/553/1013/99
DiarrhoeaGastrointestinal disorders1/574/555/1011/99

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo100 mg Inclisiran Sodium200 mg Inclisiran Sodium300 mg Inclisiran SodiumTotal
Mean63.8 ± 11.1262.7 ± 9.2564.7 ± 10.5763.0 ± 10.6663.6 ± 10.46
Sex: Female, Male
Sex: Female, Male(Participants)Placebo100 mg Inclisiran Sodium200 mg Inclisiran Sodium300 mg Inclisiran SodiumTotal
Female1819212280
Male39368077232
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo100 mg Inclisiran Sodium200 mg Inclisiran Sodium300 mg Inclisiran SodiumTotal
Japanese575510199312
08

Study locations

42 sites
  • Novartis Investigative Site
    Nagoya, Aichi, Japan
  • Novartis Investigative Site
    Matsudo city, Chiba 271 0077, Japan
  • Novartis Investigative Site
    Itoshima, Fukuoka 819-1104, Japan
  • Novartis Investigative Site
    Kitakyushu-city, Fukuoka 806-8501, Japan
  • Novartis Investigative Site
    Kitakyushu, Fukuoka 800-0057, Japan
  • Novartis Investigative Site
    Kitakyushu, Fukuoka 804-0025, Japan
  • Novartis Investigative Site
    Kitakyushu, Fukuoka 805-8508, Japan
  • Novartis Investigative Site
    Nakagawa, Fukuoka 811-1244, Japan
  • Novartis Investigative Site
    Sapporo-city, Hokkaido 006-8555, Japan
  • Novartis Investigative Site
    Sapporo, Hokkaido 062-8618, Japan
  • Novartis Investigative Site
    Sashima-gun, Ibaraki 306-0433, Japan
  • Novartis Investigative Site
    Tsuchiura, Ibaraki 300-0028, Japan
  • Novartis Investigative Site
    Kahoku-gun, Ishikawa 920-0293, Japan
  • Novartis Investigative Site
    Kanazawa-city, Ishikawa 920-8641, Japan
  • Novartis Investigative Site
    Kanazawa, Ishikawa 920 8650, Japan
  • Novartis Investigative Site
    Komatsu, Ishikawa 923-0961, Japan
  • Novartis Investigative Site
    Takamatsu city, Kagawa 760 8557, Japan
  • Novartis Investigative Site
    Fujisawa-city, Kanagawa 251-0041, Japan
  • Novartis Investigative Site
    Kawasaki-city, Kanagawa 216-8511, Japan
  • Novartis Investigative Site
    Kuse, Kyoto 613-0034, Japan
  • Novartis Investigative Site
    Sendai, Miyagi 983-0039, Japan
  • Novartis Investigative Site
    Omura, Nagasaki 856-8562, Japan
  • Novartis Investigative Site
    Izumisano-city, Osaka 598-8577, Japan
  • Novartis Investigative Site
    Matsubara-city, Osaka 580-0032, Japan
  • Novartis Investigative Site
    Osaka city, Osaka 530 0001, Japan
  • Novartis Investigative Site
    Osaka-city, Osaka 540-0006, Japan
  • Novartis Investigative Site
    Osaka-city, Osaka 543-0035, Japan
  • Novartis Investigative Site
    Suita-city, Osaka 565-0853, Japan
  • Novartis Investigative Site
    Suita, Osaka 564-8565, Japan
  • Novartis Investigative Site
    Iruma-gun, Saitama 350-0495, Japan
  • Novartis Investigative Site
    Sayama-city, Saitama 350-1305, Japan
  • Novartis Investigative Site
    Chiyoda, Tokyo, Japan
  • Novartis Investigative Site
    Chuo-ku, Tokyo 103-0027, Japan
  • Novartis Investigative Site
    Chuo-ku, Tokyo 103-0028, Japan
  • Novartis Investigative Site
    Nerima-ku, Tokyo 176-8530, Japan
  • Novartis Investigative Site
    Shinagawa-ku, Tokyo 142-8666, Japan
  • Novartis Investigative Site
    Shinjuku ku, Tokyo 160-0008, Japan
  • Novartis Investigative Site
    Chuoh-ku, 104-0031, Japan
  • Novartis Investigative Site
    Gifu, 500-8384, Japan
  • Novartis Investigative Site
    Kyoto, 612-8555, Japan
  • Novartis Investigative Site
    Oita, 870-8511, Japan
  • Novartis Investigative Site
    Saga, 840-8571, Japan
09

References and documents

Publications

  • Warden BA, Duell PB. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins. J Cardiovasc Pharmacol. 2021 Aug 1;78(2):e157-e174. doi: 10.1097/FJC.0000000000001053. PubMed 33990512 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Apr 2022, 14 months.

Results were first posted in May 2023, 1 year after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 14 months is above that.

Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2020
First posted
Dec 14, 2020
StartActual
Jan 29, 2021
Primary completionActual
Apr 18, 2022
CompletionActual
Oct 19, 2022
Results first posted
May 10, 2023
Last update
Jun 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04666298
Responsible party
Sponsor
First posted
Dec 14, 2020
Start date
Jan 29, 2021
Primary completion
Apr 18, 2022
Completion
Oct 19, 2022
Results posted
May 10, 2023
Last update
Jun 20, 2024

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion